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Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow 
limitation and an abnormal inflammatory response of the lung. Bacteria and viruses are a major 
cause of COPD exacerbations and may contribute to COPD progression by perpetuating the 
inflammatory response in the airways. Bacterial variety diminishes with increasing COPD 
severity. Respiratory viruses can colonize the lower respiratory tract in stable COPD, altering 
the respiratory microbiome and facilitating secondary bacterial infections. In this review, we 
present the most updated information about the role of bacteria and viruses in stable and exac-
erbated COPD. In our opinion, to optimize therapeutic strategies, the dynamic events involving 
bacterial–viral infections and related immune response in COPD phenotypes need to be better 
clarified. Our paper would address these points that we consider of great importance for the 
clinical management of COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by a persistent airflow 
limitation usually associated with an increased inflammatory response.1 Bronchial biop-
sies of stable mild COPD patients show increased levels of inflammatory cells compared 
with healthy nonsmokers; among these cells, CD8+ T-lymphocytes, neutrophils, and 
macrophages are prevalent.1,2 In severe COPD, while there is a decrease in the total 
number of inflammatory cells, a prevalence of inflammatory cells with phagocytic and 
proteolytic activity, such as neutrophils and macrophages, is reported.2 Acute exacerba-
tions of COPD can cause a worsening of lung function that lasts many weeks, accelerating 
the rate of lung function decline.1 Viral and bacterial infections of the respiratory system 
are a major cause of COPD exacerbations. Microbiological examination of sputum from 
COPD patients hospitalized during an exacerbation shows that infections are mostly 
associated with bacterial pathogens of the sputum, followed by combined bacteria and 
viruses or sputum viruses.3 Another study,4 followed COPD patients for 1 year, observed 
a high rate of exacerbations in one subgroup – 37% of these were caused by bacteria, 
10% by viruses, 12% by bacteria and viruses, while 14% were of undefined origin.4 Many 
investigators have observed a change of the inflammatory response in COPD patients 
during acute exacerbations, showing a general increase in the inflammatory state.2 These 
exacerbations are associated with an increase in neutrophils, T-lymphocytes, and, in some 
cases, eosinophils.4–6 Viruses and bacteria may cause acute exacerbations of COPD, or 
alternatively, they may amplify chronic inflammation in stable COPD.7
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The aforementioned data, however, come from separate 
experimental sets using different methodological approaches, 
rendering difficult a direct comparison between bacterial–viral 
loads in the lungs of COPD patients and the related immune 
host responses. To date, few data are available on the dynamic 
mechanisms of bacteria and viruses colonizing the lungs, or 
the precise relationship between these events and disease 
progression during stable and exacerbated COPD. This review 
focuses on the present knowledge regarding the microbiome 
load (either bacteria or viruses) in stable and exacerbated 
COPD. We will not deal in depth here with the immune 
response related to bacterial–viral infections, since other 
reviews have already been published on this topic and also 
because there are few in vivo data available. We will focus 
instead on the dynamic events involved in COPD progression 
and touch on future prospects for therapeutic strategies.
Role of bacteria in COPD
Stable COPD patients
Pathogenic bacteria have been identified using culture 
techniques in 25%–50% of patients with stable COPD.8 
A limitation of culture techniques, however, is the possibility 
of contamination from the upper airways. Moreover, more 
than 70% of bacterial species cannot be cultured by current 
techniques9,10 and many of the remaining species are very 
difficult to culture.11 The development of nonculture-based 
techniques, such as quantitative polymerase chain reaction 
(qPCR), has improved the capacity to detect bacteria, and 
has shown that the lungs are not sterile12,13 and that the mix of 
bacterial species composing the lung microbiome contributes 
to the disease state in chronic respiratory diseases.14
Lower airways in COPD patients are colonized by 
Streptococcus pneumoniae, Haemophilus influenzae, and 
Moraxella catarrhalis and, in patients with more severe 
disease, by Pseudomonas aeruginosa (Figure 1).15–17 Some 
studies in stable-state COPD have observed a direct cor-
relation between airway inflammation and the bacterial 
load, for example, before the advent of nonculture-based 
techniques, Hill et al17 performed sputum cultures in 160 
stable COPD patients, 55 with normal blood α
1
-antitrypsin 
levels, 62 with severe α
1
-antitrypsin deficiency, and 43 with 
idiopathic bronchiectasis, and observed that the bacterial load 
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Figure 1 Scheme representing the normal airway microbiota and human respiratory pathogens most frequently associated with COPD exacerbations.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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is correlated to airway inflammation in patients with stable 
chronic bronchitis.17 Garcha et al18 studied sputum samples 
from 134 patients by qPCR and observed that in stable COPD, 
a higher bacterial load was correlated to more severe bron-
chial obstruction, higher dosage of inhaled corticosteroids, 
and a higher C-reactive protein (CRP) level. More recently, 
Barker et al19 studied sputum samples from 120 patients with 
stable COPD and paired sputum in 55 subjects with stable 
and exacerbated disease. Using qPCR, they observed that the 
majority of patients in a stable state (76%) had pathogenic 
bacteria in their airways. The detection of bacteria by means 
of nonculture-based techniques such as qPCR was also 
associated with increased sputum interleukin (IL)-1β, IL-10, 
and tumor necrosis factor α, and decreased Chemokine (C-C 
Motif) Ligand 13 (CCL13). In a stable state, the strongest 
relationship between bacterial load, inflammation, and symp-
toms was observed with H. influenzae, whether in codetection 
with other bacteria or as sole pathogen. Singh et al20 analyzed 
the sputum of 99 stable COPD patients by qPCR and observed 
a direct correlation between the load of H. influenzae, 
S. pneumoniae, and M. catarrhalis and airway inflammation 
and plasmatic fibrinogen. Erb-Downward et al21 analyzed 
bronchoalveolar lavage (BAL) fluid of three never smok-
ers, seven healthy smokers, four COPD patients, and eight 
samples obtained from six patients undergoing lung trans-
plantation for COPD. A significant bacterial load was found 
in all subjects without significant differences between groups. 
In some smokers with normal lung function, the authors 
found a lower diversity of lung microbiota and speculated 
that this relative reduction in the diversity could be persistent 
and could be either an “effect” of the lung inflammation or, 
in part, a “cause” of disease onset and progression.21
The molecular aspects of these dynamic modifications 
in the bacterial load and bacterial types in relation to the 
patient’s immune response need to be studied. It has been 
hypothesized that the appearance of new strains of foreign 
microbes initiates a cycle of infection, inflammatory response, 
and dysfunctional remodeling driving the progression of 
COPD.17,22
Sze et al23 analyzed samples from surgical lung resec-
tions and lung transplant donors of smokers (eight samples), 
nonsmokers (eight samples), COPD patients (eight samples), 
and cystic fibrosis patients (eight samples). They showed 
differences in the bacterial community of the COPD lung 
tissue compared with other groups. Actinobacteria were 
more abundant in the smoker group, while Lactobacillus 
were consistently present in the COPD Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) 4 group. In the 
cystic fibrosis and COPD groups, the Burkholderia genus 
represented more than 5% of the bacterial community. The 
increased presence of Lactobacillus in the lung could be 
related to an inflammatory state associated to the formation 
of tertiary lymphoid follicles developing near the small 
airways.23 Lactobacillus could either be the target of the 
inflammation or, alternatively, it could act as an immune 
modulator and aid the inflammatory response. In their study, 
the authors showed that in the very severe COPD group, 
there was a shift in the relative abundance of a few bacterial 
populations without any one becoming dominant.
Relative abundance and an increasing “diversity” of the 
bacterial population in COPD was observed by Pragman 
et al24 who studied BAL samples from 22 patients with 
moderate-to-severe COPD and ten controls, and Wu et al25 
who analyzed sputum of ten COPD and control subjects. 
Garcia-Nuñez et al26 studied with nonculture-based tech-
niques the bronchial microbiome in the sputum of 17 stable 
COPD patients and observed that, in patients with more 
severe disease, the Proteobacteria phylum was overrepre-
sented, together with a diminution of bacteria belonging 
to the Firmicutes phylum. The authors speculated that 
changes in the lung microbiome in more severe COPD 
patients could be due either to alterations of the airways 
typical of very severe diseased patients or to the repeated 
use of antibiotics. The alteration in microbiome composition 
observed may induce further lung inflammation contributing 
to the worsening of the disease.26 More recently, Sze et al27 
examining 40 lung samples from five COPD (GOLD stage 4) 
subjects have confirmed the reduction in microbial diversity 
with a relative increase of Proteobacteria and Actinobacte-
ria and a reduction of Firmicutes and Bacteroidetes phyla. 
The authors, moreover, reported a significant association 
between the alterations of the microbiome, the extent of 
emphysema, remodeling of bronchi and alveoli, and their 
infiltration by CD4+ T-cells. Sze et al hypothesize that the 
increased abundance of Proteobacteria and Actinobacteria 
in COPD (GOLD stage 4) airways could stimulate a more 
intense lung inflammation.27
These findings are in contrast to other studies.24,25 The 
discrepancy could be due to the small number of patients 
analyzed in these studies and differences in study design 
(Table 1). Furthermore, the study by Erb-Downward et al21 
was based on samples obtained from BAL and bronchial 
brushes while in the study by Sze et al,23,27 the samples were 
obtained from lung tissue, rendering the findings less directly 
comparable. A limitation of the study by Sze et al23 is the 
absence of a moderate and severe COPD group (GOLD 
stage 2 and 3) that leaves open the question whether the 
emergence of Lactobacillus and Burkholderia in the lungs is 
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gradually progressive or a sudden occurrence. Pragman et al24 
studied BAL samples while Garcia-Nuñez et al26 analyzed 
sputum samples. Other facts influencing the findings are the 
heterogeneity of the COPD population: in some patients, 
there is a predominance of emphysema, while in others, 
chronic bronchitis is prevalent; moreover, the different drugs 
used to treat the disease in COPD patients could have altered 
the lung microbiome: some patients were treated with antibi-
otics and others with steroids or β2 agonists. A well-defined 
washout period from antibiotic and corticosteroid use is not 
reported in these studies. Some studies considered COPD 
patients in a stable state after 4 weeks had lapsed from the 
last exacerbation.19–30 One study indicated the antibiotics used 
during the exacerbation phase of the patients but no data are 
available about the dose of corticosteroid during that phase.30 
One study reported the antibiotic dosage used.26 Since many 
of these studies use a quantitative approach quantitative 
reverse transcriptase-polymerase chain reaction (qRT-PCR) 
for microbiome evaluation, it is mandatory to define precisely 
the pharmacologic treatments and the washout duration for 
antibiotics and corticosteroids. We suggest that a 3-month 
washout period for antibiotic treatment, and at least 1-month 
washout for oral or inhaled corticosteroid use should be con-
sidered when evaluating COPD patients in stable conditions. 
Even with the limitations described and the need for studies 
with larger sample size and a well-defined pharmacological 
treatment regimen, it appears that the airways of COPD 
patients have a different microbiome and a larger number 
of bacteria compared with normal subjects.
There is rather concordance on the fact that with the 
progression of the disease, there is a reduction in the microbial 
diversity with an increase of some phyla (Proteobacteria and 
Actinobacteria) and a reduction of others that are normally 
present in COPD.
exacerbated COPD patients
The role of bacterial pathogens during COPD exacerbations 
has recently been further investigated. Exacerbations of 
COPD are associated with changes in respiratory microbiota 
and airway inflammation.
In 2002, Sethi et al22 followed 81 COPD patients for 
56 months, studying their sputum with culture-based tech-
niques during stable disease and exacerbations, and observed 
that the isolation of new strains of pathogens was associated 
with an increased risk of exacerbations.22
The development of nonculture-based techniques for 
bacterial isolation has shed more light on the role of bacteria 
during an exacerbation process. Huang et al28 studied eight 
patients admitted to an intensive care unit for COPD exacer-
bation. Samples were obtained from endotracheal aspirates. 
Using nonculture-based techniques (qPCR), the authors 
observed a much greater diversity of bacteria than hitherto 
realized with culture techniques. Multiple oropharyngeal- and 
gut-associated bacterial species were isolated, suggesting a 
Table 1 Breakdown of different bacterial microbiota studies in COPD
Study
(reference)
Control 
subjects
COPD 
patients
Sampling 
method
Predominant 
stage of COPD
Microbes evaluated Location of study 
population
Cytokines/biomarkers 
correlated with bacteria
18 0 143 Sputum 2–3 (stable vs 
exacerbated)
Hem, Strep, Mor Out CRP
19 0 120 Sputum 2–3 (stable vs 
exacerbated)
Hem, Strep, Mor Out IL-1B, IL-8,
IL-10, TNF-α
20 0 99 Sputum 2 Hem, Strep, Mor Out CXCL8,
IL-IB, MPO
21 10
0
4
6
BAL fluid
tissue
1
4
Total bacterial community Out
In
na
23 16 8 Tissue 4 Total bacterial community In na
24 10 22 BAL fluid 2 Total bacterial community Out na
25 10 10 Sputum na Strep, Kleb, Pseud Out na
26 0 17 Sputum 2–3–4 Total bacterial community Out na
27 4 5 Tissue 4 Total bacterial community In na
28 0 8 endotracheal 
aspirates
4 (exacerbated) Total bacterial community ICU na
29 0 16 Sputum 3–4 (stable vs 
exacerbated)
Total bacterial community Out na
30 0 12 Sputum 2–3 (stable vs 
exacerbated)
Total bacterial community Out na
Abbreviations: BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CXCL8, CXC-chemokine ligand 8; Hem, Haemophilus 
influenzae; ICU, intensive care unit; IL-1B, interleukin 1B; IL-8, interleukin 8; IL-10, interleukin 10; In, inpatients; Kleb, Klebsiella pneumoniae; Out, outpatients; Mor, Moraxella 
catarrhalis; MPO, myeloperoxidase; na, not available; Pseud, Pseudomonas aeruginosa; Strep, Streptococcus pneumoniae; TNF-α, tumor necrosis factor α.
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potential role of these strains in COPD exacerbations. Huang 
et al, hypothesized the presence of two bacterial micro-
biota related to exacerbated COPD, one characterized by a 
prevalence of Proteobacteria, the other by a prevalence of 
Firmicutes, which might be associated with more diversity.28 
The patients in the group with prevalence of Firmicutes were 
those with a shorter intubation period before performing the 
endotracheal aspirate. Moreover, a decreased bacterial diver-
sity was correlated with the length of intubation.28 It can be 
speculated that antibiotic treatment could have reduced the 
bacterial diversity. The limits of this study were the absence 
of control samples from non-intubated COPD and non-COPD 
patients and the lack of a longitudinal dimension. Bacteria 
in the oral cavity and gastrointestinal tract seed the airways 
in vulnerable patient populations.24 Millares et al29 analyzed 
paired sputum specimens from patients with COPD at base-
line and during exacerbations, and found that exacerbations 
were associated with a selective increase in the relative 
abundance of bacteria typically associated with exacerbations 
(eg, Haemophilus, Pseudomonas, and Moraxella) despite 
inconsistent detection in culture. Huang et al30 observed 
the temporal changes in the airway microbiome before, at 
onset, and after an acute exacerbation. They studied bacte-
rial infections in COPD sputum samples from 12 subjects 
enrolled in a longitudinal study: the microbiota members 
that resulted increased during exacerbations, were mainly 
of the Proteobacteria phylum. Treatment with antibiotics 
alone decreased the Proteobacteria, whereas treatment with 
corticosteroids alone enriched the Proteobacteria and other 
phyla. Neither of these two studies29,30 reported a decrease 
in bacterial community diversity, as would be expected after 
an acute infection or in more severe disease.
For a better understanding of the role of the microbiome 
in exacerbations of COPD, there is a need for longitudinal 
studies in exacerbated conditions after a sufficiently extended 
stabilization period, including appropriate washout from 
pharmacological treatments, as well as in nontreated controls. 
The parallel analysis of the immunological host response 
associated with these different clinical states in COPD 
patients also needs to be longitudinally conducted.
In the studies reported here, there is no grading of the 
severity of exacerbations. Indeed, some exacerbated COPD 
patients need only a change in medication at home, while 
others need to be admitted to the intensive care unit. Studies 
are required, in our opinion, to address this issue, that is, to 
classify the exacerbation process related to its severity.31 Also 
severity of bronchial obstruction during stable conditions 
could be considered in the grading scheme of exacerbations. 
In addition, more studies are needed to characterize the 
microbiome during COPD exacerbations. A list of the studies 
already carried out is reported in Table 1.
Role of viruses in COPD
Stable COPD patients
The use of PCR-based approaches to amplify virus-specific 
nucleic acid sequences has documented the invasion of respi-
ratory viruses into the peripheral airways of COPD patients 
both during acute exacerbations and in stable conditions.32–36 
Some authors suggest that, in stable COPD, virus coloniza-
tion could play a role in maintaining the elevated inflamma-
tory background.
Utokaparch et al35 with qPCR in frozen lung tissue 
from 20 GOLD stage 1 COPD patients in stable state and 
20 healthy smoker controls, detected viral nucleic acid in 
18/40 patients. The two most common viruses detected 
were influenza virus A and coronavirus 229E, each isolated 
in 10/40 samples.35 Influenza virus was more prevalent in 
COPD patients than in control subjects (40% vs 10%). COPD 
patients had a greater total viral load and a greater number of 
viruses per patient compared with healthy controls.37 Mallia 
et al37 also showed a significant inverse relationship between 
the forced expiratory volume in 1 second/forced vital capacity 
ratio and the number of macrophages and neutrophils in the 
small airways, and a direct relationship between inflamma-
tory cells and total viral load. The authors postulated that 
viruses might act as a pathogen reservoir in COPD. COPD 
patients are considered more susceptible to virus infection 
and persistence of infection.
Again, the relationship between the degree of inflam-
mation and viral load needs to be studied in patients under 
well standardized therapeutic conditions. Corticosteroid 
use could have favored the persistence of viruses in the 
airways, as observed by Utokaparch et al35 and Mallia 
et al.37 Yet only in the study by Mallia et al37 is antibiot-
ics courses and exacerbations in the last year before the 
enrolment of patients documented. Specific information on 
antibiotics or corticosteroid use is infrequently available in 
other studies.35–37
exacerbated COPD patients
Respiratory viral infections are traditionally those implicated 
in COPD exacerbations. Rhinovirus, coronavirus, influenza, 
respiratory syncytial viruses, parainfluenza, adenovirus, 
and metapneumovirus are the viruses that most often cause 
common cold in healthy individuals, and they play a role in 
acute exacerbations of COPD.35–38 These exacerbations can 
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be more or less severe with more or less prolonged recovery 
times.
Numerous data from 1980 onward show an acute decline 
in forced expiratory volume in 1 second in COPD patients for 
up to 90 days after an acute infection of influenza virus.39
Recently, it was demonstrated that infection by respiratory 
viruses could influence the bacterial microbiome in patients 
with COPD, and vice versa. Molyneaux et al36 infected 14 
COPD subjects and 17 healthy controls having normal lung 
function with rhinovirus and observed only in the sputum of 
COPD patients a rise in the bacterial load and a significant 
prevalence of H. influenzae with respect to the existing micro-
biota. The authors suggested that rhinovirus infection in COPD 
alters the respiratory microbiome and may induce secondary 
bacterial infections. There is a parallel increase in the inflam-
matory response after concomitant bacterial and viral infections 
in COPD. Wilkinson et al40 observed that COPD exacerbations 
due to a rhinovirus and H. influenzae coinfection are associated 
with an increased level of serum IL-6 compared with exacerba-
tions where only one pathogen was isolated. Similar findings 
have been reported by Mallia et al:37 the authors observed 
that 60% of COPD patients experienced a secondary bacterial 
infection after being infected with rhinovirus.
These data have been confirmed by histologic analyses 
of infected lung samples from patients who died from 1918 
type A and 2009 H1N1 influenza.41–43 In these patients, the 
predominant cause of death was a bacterial superinfection 
resulting in secondary bacterial pneumonia. In mice, the 
infection of influenza A virus increases the susceptibility 
to bacterial respiratory infections such as S. pneumoniae, 
Staphylococcus aureus, and H. influenzae.44,45 Influenza 
virus may cause this susceptibility to bacterial superinfec-
tion through various mechanisms. The damage of the epithe-
lial cells and alterations of the epithelium by viral infection 
can facilitate the bacterial colonization of the airways.46 
Another mode by which influenza virus can favor bacterial 
infection is by altering the function of the immune system, 
resulting in a failure of the control of bacterial replication 
(Figure 2).
Influenza A virus causes apoptosis and alters the function 
of alveolar macrophages,47,48 suppressing their activation in 
response to secondary bacterial challenge and phagocytic 
capacity by increasing the expression of CD 200 receptor 
ligation antigen49 and reducing the expression in the alveolar 
macrophages of the scavenger macrophage receptor with col-
lagenous structure (MARCO).48 The macrophages’ reduced 
production of cytokines and chemokines alters the response 
of other cells to pathogens, reducing for example the recruit-
ment and activation of neutrophils. Neutrophil function is 
also altered by influenza A virus either through direct infec-
tion of the cells50 or through the induction of type I interferon 
secretion that leads to the inhibition of neutrophil infiltration 
and increased apoptosis.51 Natural killer cells are also affected 
by influenza virus: in an infected lung, they show a reduction 
of cytotoxic activity and the production of chemokines and 
cytokines52 such as the antibacterial effector cytokine tumor 
necrosis factor.53 There is evidence that the induction of a 
highly polarized type 1 T helper (Th1) immune response by 
respiratory viruses leads to a reduction of MARCO expres-
sion and impairs macrophages’ ability to ingest and kill 
bacteria.48 The fine balance of IL-10 production and Th17 
response during a viral infection could explain the excessive 
susceptibility to the bacterial superinfection observed after 
influenza virus infection.54,55 van der Sluijs et al56 observed 
that blocking IL-10 production enhanced the clearance of a 
secondary infection of S. pneumoniae. Another effect due to 
increased type I interferon production following influenza 
virus infection is the suppression of the Th17 response during 
a secondary bacterial infection in mice.57
These data suggest that Th17 cells are important in 
organizing the immune response to bacteria such as S. pneu-
moniae and S. aureus. Viral inhibition of this pathway may 
form the basis of the increased secondary bacterial infections 
and the worst outcome in COPD patients.
Interestingly, Perera et al58 observed that higher serum 
CRP levels in COPD patients 14 days after the first 
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Figure 2 Representation of the known mechanisms proposed to explain how 
influenza virus favors bacterial outgrowth.
Notes: Bronchial epithelial damage is followed by a decrease of neutrophils 
recruitment, NK activity, and Th17 numbers and activity. Alveolar epithelial damage 
could be followed by a decrease of alveolar macrophage numbers and activity.
Abbreviation: NK, natural killer.
International Journal of COPD 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
451
Microbiome and immune response in COPD
exacerbation episode were correlated with a shorter time 
to the next exacerbation. Moreover, frequent exacerbators 
had higher serum levels of IL-6 and CRP in comparison to 
infrequent exacerbators. The authors suggested that these 
higher inflammatory indices in frequent exacerbators could 
be related to the faster forced expiratory volume in 1 second 
decline and increased mortality seen in this subgroup of 
patients.58 Nonrespiratory viruses such as human immuno-
deficiency virus can change the lung microbiome facilitat-
ing colonization by pathogenic gastrointestinal bacteria in 
infected patients.59,60
There are relatively few data available concerning viral 
infections in COPD patients caused by influenza virus A, cor-
onavirus, Respiratory syncytial virus, and rhinovirus.35–37,39 
Among nonrespiratory viruses involved in COPD exacerba-
tions and lung microbiome alterations, data are limited only 
to human immunodeficiency virus infections.59,60 Moreover, 
these studies included only patients with mild COPD.35–37,39 
As a consequence, further studies investigating the host 
immune response in relation to different stages and pheno-
types of COPD patients are needed.
Specific data between viral and bacterial infections in 
stable and exacerbated COPD, in relation to the host immune 
response, need to be produced to gain a clearer picture 
on its interrelationship and related immune processes in 
COPD.
Conclusion
COPD is an illness characterized by an abnormal inflamma-
tory response of the lung. The inflammatory cell infiltration in 
the airways of these patients varies according to the stage of 
the disease. Recent findings show that the immune response 
is impaired in the COPD lung.61
The microbiome in the airways of COPD patients is 
altered with increasing disease severity, and during the 
exacerbation process. Alterations of the normal bacterial 
populations in COPD patients with a reduction of bacterial 
variety are associated with an increased risk of exacerba-
tion and severity, and bacteria and viruses play a pivotal 
causal role in COPD exacerbations and disease progres-
sion. Stable COPD patients can harbor respiratory viruses 
in their airways. Bacteria and viruses in the lungs could 
play a role in maintaining the inflammatory state in COPD 
patients during the stable phase. There is evidence that the 
bacterial and viral loads in the airways of stable COPD are 
directly correlated to the airways inflammation. Some studies 
evidence that some bacterial phyla such as Proteobacteria 
are more capable of stimulating inflammation in the airways 
of COPD patients.
To date, it is still not clear how some bacteria can influ-
ence the inflammatory response in the lungs and how lung 
virus infection/colonization can alter the local microbiome. 
In other words, the dynamic process involving bacterial and 
viral challenges that is able to change the clinical status of 
patients in relation to the host innate and adaptive immune 
response needs to be better explored.
The genetic changes probably present in COPD at differ-
ent stages (severe vs mild) or having different phenotypes 
(frequent exacerbators vs nonfrequent) were outside the 
scope of the present review. Well-planned studies applying 
appropriate washout periods from therapeutic treatments 
of COPD patients in different clinical conditions are also 
needed for a correct quantitation of the microbiome in 
these different clinical states. Understanding the dynamics 
of the lung microbiome in different clinical conditions and 
the interactions with the related endogenous host immune 
response will improve our knowledge of the pathologic and 
molecular mechanisms underlying COPD, as a consequence 
enabling the development of new therapeutic strategies to 
limit the progression of the disease.
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